



PDF
Complete

*Your complimentary
use period has ended.
Thank you for using
PDF Complete.*

[Click Here to upgrade to
Unlimited Pages and Expanded Features](#)



«

»



PDF Complete
 Your complimentary use period has ended.
 Thank you for using PDF Complete.

[Click Here to upgrade to Unlimited Pages and Expanded Features](#)

2009

í . 3

Abstract í . 5

1.0 í . 7

1.1 : í . 7

1.2 í . 9

1.3 í . 11

1.4 ø

ó TUEs í . 13

1.5 í . 15

2.0 í . 16

2.1 í . 16

2.2 í . 19

2.3 í . 25

3.0 í . 34

4.0 í . 37

5.0 í . 47

6.0 í . 53

7.0 í . 55



PDF Complete

Your complimentary use period has ended.
Thank you for using PDF Complete.

[Click Here to upgrade to Unlimited Pages and Expanded Features](#)

2004 (APG).

doping

Doping (DCOR),

∅

(TUE).

: 64.2%

doping

81.3%

4

ó

(42.1%),

(NSAIDs)

(9.8 5.6%,

).

-2-

APG (4.8%)

(AOG).



PDF Complete
Your complimentary use period has ended.
Thank you for using PDF Complete.
[Click Here to upgrade to Unlimited Pages and Expanded Features](#)

zolpidem,

AOG.

2004,

Food Supplements by Athletes during the Athens 2004 Paralympic Games

Abstract

Objective: To gather data and examine the use by elite Paralympic athletes of food supplements and pharmaceutical preparations.

Design: Survey study.

Setting: Athens 2004 Paralympic Games (APG).

Participants: Data from 2 sources were collected: athletes' declaration of medications/supplements intake recorded on the Doping Control Official Record (DCOR) during sample collection for doping control, and athletes' application forms for granting of a therapeutic use exemption (TUE).

Main Outcome Measurements: Classification of declared food supplements according to the active ingredient and medications according to therapeutic actions and active compounds.

Results: 64.2% of the athletes tested for doping control declared use of medications or food supplements and 81.3% declared intake of less than 4 preparations. Non-invasive routes of administration dominated. Food supplements (42.1%) remained popular and medications used to treat several pathological conditions were recorded. Non-steroidal anti-inflammatory agents (NSAIDs) and analgesics were also commonly used by athletes (9.8 and 5.6%, respectively). The prevalence of inhaled beta-2-agonist use at the APG (4.8%) was higher than anticipated and exceeded that at the Athens Olympic Games (AOG). The declared use of benzodiazepines, zopiclone and zolpidem, as they are banned Narcotics under the 3459/06 Hellenic Law, along with injected haemoderivatives, warrants comment.

Conclusions: This review, the first to deal with elite Paralympic athletes, demonstrates a more rational approach to the use of medication and food supplements and a similar



Your complimentary
use period has ended.
Thank you for using
PDF Complete.

[Click Here to upgrade to
Unlimited Pages and Expanded Features](#)

Nevertheless, since there are rather few studies, the
ic athletes are not yet clear. The need to counsel athletes
with disabilities on their nutritional needs is confirmed and close monitoring by health care
professionals is required.

Key Words: Paralympic Games Athens 2004, therapeutic use exemptions, food supplements,
medications



PDF Complete

Your complimentary use period has ended.
Thank you for using PDF Complete.

[Click Here to upgrade to Unlimited Pages and Expanded Features](#)

1948, Sir Ludwig Guttmann

Stoke Mandeville ().

1960,

(). 1976 ,

("IPC Brochure").

400

23

1960 3.951

146

2008 ("History of Sport for Persons with

a Disability").

().

1988

Albertville 1992

19 2001,

(IOC)

(IPC)

2012 ,



PDF Complete
 Your complimentary use period has ended.
 Thank you for using PDF Complete.
[Click Here to upgrade to Unlimited Pages and Expanded Features](#)

().

2012 Sochi 2014 ("History of Sport for Persons with a Disability"; "Paralympic Games").

IPC,

-Doping (WADA)

-Doping (WADC)

[(ó IST,

ó ,

ó ISL, ø

ó TUEs) ("World Anti-Doping

Agency, International Standard for Laboratories, 2004"; "World Anti-Doping Agency,

International Standard for Therapeutic Use Exemptions 3.0, 2003"; "World Anti-Doping

Agency, International Standard List of Prohibited Substances and Methods"; "World Anti-

Doping Agency. International Standard for Testing 3.0. Montreal: World Anti-Doping

Agency; 2003"). IPC WADC,

-Doping IPC ("IPC Anti-Doping Code,"),

doping , ø

WADC:

✓

doping ,



PDF Complete
Your complimentary use period has ended.
Thank you for using PDF Complete.
[Click Here to upgrade to Unlimited Pages and Expanded Features](#)

doping.

1.2.

:

- i.
- ii.
- iii. 6
- iv.
- v. *Les autres:*

Classification () ("IPC Classification Code,").

[Click Here to upgrade to Unlimited Pages and Expanded Features](#)

(Classifiers).

IPC 27

, 20 , 5

2 -

1

("Sports,").

1.

("2004 Annual Report,"; "Paralympic Games,"; "Sports,").

1

, les autres

2

6
()

3

(Boccia)

(CPISTRA)

4

5

6

(5x5)

(IBSA)

7

(7x7)

(CPISTRA)

[Click Here to upgrade to Unlimited Pages and Expanded Features](#)

9	(IBSA),			
10			,	, <i>les autres</i>
11	(IFDS)		,	,
12			<i>les autres</i>	,
13			,	,
14	(ITTF)		<i>les autres</i>	,
15	()	(WOVD)		,
16				,
17	(IWAS)			,
18	(IWAS)		()	
19				
20	(FISA)		2005,	

13.

2004 3.806 136 ,



[Click Here to upgrade to
Unlimited Pages and Expanded Features](#)

-
- *les autres*

("2004 Post Games Report").

2

2. (Nyland, Snouse, Anderson, Kelly, & Sterling, 2000)



10%

«

».

(<20/200).

[Click Here to upgrade to
Unlimited Pages and Expanded Features](#)

«les autres»

(*osteogenesis imperfecta*),

137

, 4), 9

, 58

20 (3 , 13

4 8.

1.4. ø

ó TUEs)

WADC,

doping.

(TUE),

(aTUE),



(GCSs)

∅ .

doping

TUEs aTUEs

doping ("World Anti-Doping Agency, International Standard for Therapeutic Use Exemptions 3.0, 2003").

6 -doping IPC ("IPC Anti-Doping Code")

WADA. IPC,

IPC

IPC

(, , , , , , , ,) TUE .

IPC (Boccia,

, 5x5, 7x7, , Goalball, ,

, , , Rugby)

TUEs (TUEC) IPC



PDF Complete
Your complimentary use period has ended.
Thank you for using PDF Complete.
[Click Here to upgrade to Unlimited Pages and Expanded Features](#)

(patterns) /

(Corrigan & Kazlauskas, 2003a; Huang, Johnson, & Pipe, 2006a; Tsitsimpikou et al., 2009).

1960.

∅

DCOR

doping,

TUE

2004.

()

(Ferrara & Peterson, 2000; Reynolds, Stirk, Thomas, & Geary, 1994).

426

(NWAA),

(USABA)

(USCPAA).

3.

/

1996 (Nyland et al., 2000).

3.

/

(Ferrara et al.,

1992; Klenck & Gebke, 2007)

	(%)
(NWAA)	(57%)
(USABA)	(53%)
(USCPAA)	(21%),

4

[Click Here to upgrade to Unlimited Pages and Expanded Features](#)

(Dec, Sparrow, & et al., 1992; Klenck & Gebke, 2007; Nyland et al., 2000; Quignan, 2004)

✓	/	✓	
✓			
✓		✓	
✓	()	✓	,
✓		✓	/
✓			
	(,)	✓	,
		✓	
	(,)	✓	/ /
		✓	()
			-
			,
			,
/			(),
	()	✓	
		✓	
		✓	
,	/		,
,		✓	
		✓	
		✓	
		✓	
		✓	,

[Click Here to upgrade to Unlimited Pages and Expanded Features](#)

- ✓
- ✓
- ✓

- ✓ NSAIDS(*)
- ✓ GCSs
- ✓
- ✓
- ✓
- ✓ NSAID
- ✓
- ✓
- ✓
- ()

(stretching)

,

(diazepam, lorazepam)

,

(... ,)

()

,

- ✓
- ✓

(
-
,
,
/)

- ✓
- ✓
- ✓

/

[Click Here to upgrade to
Unlimited Pages and Expanded Features](#)

(

,

,

)

,

,

,

(*):NSAIDs

(*on-Steroidal Anti-Inflammatory Drug*)

2.2.

,

∅



PDF Complete
 Your complimentary use period has ended.
 Thank you for using PDF Complete.
[Click Here to upgrade to Unlimited Pages and Expanded Features](#)

("European Parliament-Directive 2002/46/EC of the 10th June 2002 on the approximation of the laws of the

Member States relating to food supplements").

()

(2000/13/EC/20-03-00) ("European Parliament-Directive 2000/13/EC of the European Parliament and Council of 20th March 2000 on the approximation of the laws of the Member States relating to the labeling, presentation and advertising of foodstuffs").

(Geyer et al., 2004; Green, Catlin, & Starcevic,

2001)

, ø « » . ø

51 10.274

15 ,

46%.

ó .

(Sobal & Marquart, 1994a).

3,8



(Huang, Johnson, & Pipe, 2006b).

(Corrigan & Kazlauskas, 2003b),

()

(Corrigan & Kazlauskas, 2003a; Tsitsimpikou et al., 2009).

(Sobal &

Marquart, 1994b).

(Phillips, 2004),

(BCAA)

(Kreider, 1999).

35%

doping

(Tsitsimpikou et al., 2009).

(Corrigan & Kazlauskas, 2003b; Sobal & Marquart, 1994a;

Tsitsimpikou et al., 2009),



PDF Complete
Your complimentary use period has ended.
Thank you for using PDF Complete.
[Click Here to upgrade to Unlimited Pages and Expanded Features](#)

("Joint Position Statement: nutrition and athletic performance. American College of Sports Medicine, American Dietetic Association, and Dietitians of Canada," 2000).

(Kreider, 2003; Mesa, Ruiz, Gonz alez-Gross, Guti errez S ainz, & Castillo Garz on, 2002; Terjung et al., 2000). (Alaranta, Alaranta, Heli ovaara, Airaksinen, & Helenius, 2006; Corrigan & Kazlauskas, 2003a; Huang et al., 2006a; Tsitsimpikou et al., 2009)

(Volek & Rawson, 2004).

("Joint Position Statement: nutrition and athletic performance. American College of Sports Medicine, American Dietetic Association, and Dietitians of Canada," 2000).

(<2.5%) (Corrigan & Kazlauskas, 2003a; Tsitsimpikou et al., 2009),

 



PDF Complete

Your complimentary use period has ended.
Thank you for using PDF Complete.

[Click Here to upgrade to Unlimited Pages and Expanded Features](#)

(Forgac, 1980; Haff,

(Grunewald & Bailey, 1993; Schwenk & Costley, 2002).

1.

2.



PDF Complete

*Your complimentary use period has ended.
Thank you for using PDF Complete.*

[Click Here to upgrade to Unlimited Pages and Expanded Features](#)

4.

1%,

5.



PDF Complete

Your complimentary use period has ended.
Thank you for using PDF Complete.

[Click Here to upgrade to Unlimited Pages and Expanded Features](#)

(Schwenk & Costley, 2002).

2.3.

doping

TUE,

, NSAIDs,



PDF Complete
Your complimentary use period has ended.
Thank you for using PDF Complete.
[Click Here to upgrade to Unlimited Pages and Expanded Features](#)

(Thuyne & Delbeke, 2008a).

2002
34,5%
7
24,9%
(. . NSAIDs, . . .)

(Alaranta et al., 2006).

NSAIDs
NSAIDs

(Almekinders, 1999; Rahusen, Weinhold, & Almekinders, 2004).

(De Meersman, 1988; Roi et al., 1994).

NSAIDs () (Corrigan & Kazlauskas, 2003a),

25%

doping,

(Corrigan & Kazlauskas, 2003a; Huang et al., 2006a;

Tsitsimpikou et al., 2009),

(Skouroliakou, Kani,



PDF Complete
 Your complimentary use period has ended.
 Thank you for using PDF Complete.
 Click Here to upgrade to Unlimited Pages and Expanded Features

05).

NSAIDs

(Alaranta et al., 2006; Huang

et al., 2006a),

/

Softball,

NSAIDs

45%

pitchers

(Meyers, Brown, & Bloom, 2001a).

18.645

NSAIDs

18% (Thuyne &

Delbeke, 2008a).

2001

(W Van Thuyne & Delbeke, 2002).

NSAIDs

(Corrigan & Kazlauskas, 2003a; Tannenbaum et al., 1996).

NSAIDs (Alaranta et al., 2006; Baldwin Lanier, 2003)

NSAIDs

(Corrigan

& Kazlauskas, 2003a; Tsitsimpikou et al., 2009).

NSAIDs

(Szczeklik, 1987).

(Thuyne & Delbeke, 2008a; Tsitsimpikou et al.,

2009).

(UCI) (Thuyné & Delbeke, 2008a).

doping,

1 g/ml.

("World Anti-Doping Agency, International Standard List of Prohibited Substances and Methods").

Carl Koller

(Altman, Albert, & Fournier,

1985),

doping ("World Anti-Doping Agency, International Standard List of Prohibited Substances and Methods,").

(Estorch et al., 2004; Stahl & Grady, 2003).

dopexine

(Krommydas et al., 2005).

WADA


doping.



PDF Complete
 Your complimentary use period has ended.
 Thank you for using PDF Complete.
 Click Here to upgrade to Unlimited Pages and Expanded Features

GCSs
 (
 .
 , GCSs
 .
 , GCSs
 .
 ,
 GCSs : 197561984
 , 2002
 (,) (Ken Fitch & Kinsella, 2004).
 , (, , , ,)
 , , TUE ("World Anti-Doping Agency, International Standard for Therapeutic Use Exemptions 3.0, 2003"; "World Anti-Doping Agency, International Standard List of Prohibited Substances and Methods"). H
 GCSs 2,5 ó 3,0% (Corrigan & Kazlauskas, 2003a; Thuyne & Delbeke, 2008a; Tsitsimpikou et al., 2009)
 (Ken Fitch & Kinsella, 2004; Thuyne & Delbeke, 2008b). **1** GCSs
 TUEs.

Click Here to upgrade to Unlimited Pages and Expanded Features



1: GCSs (Ken Fitch &

Kinsella, 2004)

: SW: , CY: , HO: Hockey, TR: , DV: , WL: , JU: , MP: , SO: softball, D: badminton

(Lemanske,

2000; Nystad, 2000),

(Vacek, 1999),

10 ó 15% (Fitch et al., 2008; Storms,

1999). 2 ó ,

(5)

Kujala

(2003),

NSAIDs



PDF Complete
 Your complimentary use period has ended.
 Thank you for using PDF Complete.
 Click Here to upgrade to Unlimited Pages and Expanded Features

na, & Kaprio, 2003).

5. 2 ó (1984 2004) (Tsitsimpikou et al., 2009)

	UEs		%
1984, Los Angeles	119	6802	1.7
1996, Atlanta	383	10677	3.6
1998, Nagano	128	2296	5.6
2000, Sydney	607	11087	5.5
2004,	517	10563	4.9

:¹ Seoul, 1988
 TUE.
 2 45

, 1992

2 ó

. (Caruso et al., 1995; Martineau, Horan, Rothwell, & Little, 1992). , 2 ó

2 ó

TUE,


("World Anti-Doping Agency,

International Standard List of Prohibited Substances and Methods"). 2

2 ó

doping (Tsitsimpikou et al., 2009).

Click Here to upgrade to Unlimited Pages and Expanded Features



2.

2 ó

doping (AAF)

: SW: Hockey, AT: , CY: , RO: , CA: Canoe-Kayak, HO: , FB: , TR: , SA: , WP: , BK: , JU: , MP: , VO:

20-40

67%

(Komarow & Postolache, 2005). Helbling 2.961

68

16,8%

59%

1990).

(Helbling, Jenoure, & Mèuller,

(Katelaris,

Carrozzi, Burke, & Byth, 2006).

(Nieman, 2000),



*Your complimentary
use period has ended.
Thank you for using
PDF Complete.*

[Click Here to upgrade to
Unlimited Pages and Expanded Features](#)

DCORs

TUEs.

, DCOR

/

(1).

81,9%

UEs

("World Anti-Doping Agency, International Standard List of Prohibited Substances and Methods,")

TUEC IPC,

IPC,

IPC

a UEs,

UEs.

DCORs 680

(34,3±7,8 , : 18 ó 61) 492

UEs.

Martindale 32nd edition (PhP) (*Martindale: The Complete Drug Reference,*

April 1999).

(K, Na, Ca, Mg, Fe, Zn, I) ó

Click Here to upgrade to Unlimited Pages and Expanded Features

Contrôle du Dopage / Επίσημη Αναφορά Ελέγχου Dopage

Reference No.

Athlete Information/Information Concernant le Sportif/Προσωπικά Στοιχεία Αθλητή	
Event/Epreuve/Διοργάνωση	Sport/Sport/Aθλημα
Venue/Site/Τόπος	
Surname/Όνομα/Επίθετο	First Name/Όνομα/Όνομα
Date of birth/Date de naissance/Ημερομηνία Γέννησης	
Gender/Σεξ/Φύλο	Country/Πατρις/Χώρα
Accreditation No No d'accréditation Αριθμός άδειας άσκησης	

Partial Sample/Echantillon partiel/Εμπρόσθιο δείγμα	
Sample Collection Time Heure de prélèvement de l'échantillon Ώρα συλλογής δείγματος	Date Date Ημερ/Νία
Volume Volume Όγκος	Sample Code No No de code de l'échantillon Κωδικός δείγματος
Athlete's Signature Signature du Sportif Υπογραφή Αθλητή	Name & Signature DCO Nom & Signature F.ACD Όνομα & Υπογραφή Υπευθύνου Ελέγχου Dopage

Partial Sample/Echantillon partiel/Εμπρόσθιο δείγμα	
Sample Collection Time Heure de prélèvement d'échantillon Ώρα συλλογής δείγματος	Date Date Ημερ/Νία
Volume Volume Όγκος	Sample Code No No de code de l'échantillon Κωδικός δείγματος
Athlete's Signature Signature du Sportif Υπογραφή Αθλητή	Name & Signature DCO Nom & Signature F.ACD Όνομα & Υπογραφή Υπευθύνου Ελέγχου Dopage

Final Sample / Echantillon Final / Τελικό δείγμα	
Sample Collection Time Heure de prélèvement d'échantillon Ώρα συλλογής δείγματος	Date Date Ημερ/Νία
Volume Volume Όγκος	Sample Code No No de code de l'échantillon Κωδικός δείγματος
Athlete's Signature Signature du Sportif Υπογραφή Αθλητή	Name & Signature DCO Nom & Signature F.ACD Όνομα & Υπογραφή Υπευθύνου Ελέγχου Dopage

Additional Sample / Echantillon Additionnelle / Συμπληρωματικό δείγμα	
Sample Collection Time Heure de prélèvement de l'échantillon Ώρα συλλογής δείγματος	Date Date Ημερ/Νία
Volume Volume Όγκος	Sample Code No No de code de l'échantillon Κωδικός δείγματος
Athlete's Signature Signature du Sportif Υπογραφή Αθλητή	Name & Signature DCO Nom & Signature F.ACD Όνομα & Υπογραφή Υπευθύνου Ελέγχου Dopage

Name and comments Nom et commentaires Όνομα και σχόλια	Date last taken Date de la dernière prise d'un médicament Τελευταία Ημερομηνία λήψης	Dosage Doseologie Δοσολογία	Name and comments Nom et commentaires Όνομα και σχόλια	Date last taken Date de la dernière prise d'un médicament Τελευταία Ημερομηνία λήψης	Dosage Doseologie Δοσολογία

Comments / Commentaires / Παρατηρήσεις

All samples will be sent to a WADA accredited laboratory / Tous les échantillons seront remis au laboratoire accrédité par l'AMA / Όλα τα δείγματα θα αποσταλούν σε διαπιστευμένο εργαστήριο από τον WADA.

Minor irregularities which cannot reasonably be considered to have affected the results of otherwise valid tests shall have no effect on the results. / Les irrégularités n'ayant pas eu raisonnablement affecté les résultats de contrôles étant valides seront tolérées. / Οι ελαφρώς ελλοχεύουσες ανωμαλίες που δεν αλλοιώνουν τα αποτελέσματα είναι ανεπίσημες. / Je certifie que les informations fournies ci-dessus sont complètes et exactes. / Ο υπογράφων αθλητής/η τρέφει ότι όλες οι πληροφορίες που αναφέρονται παραπάνω είναι πλήρεις και ακριβείς.

Signature of Athlete/Signature du Sportif/Υπογραφή Αθλητή

Name & Signature of DCO/Nom & Signature de l'ACD/Όνομα & Υπογραφή Υπευθύνου Ελέγχου Dopage

Name & Signature of IOC/MC/IPC Representative/Nom & Signature du Représentant de la CMO/IPC
Όνομα & Υπογραφή Εκπροσώπου ΔΟΕ/ΑΠΕ
White card IOC/MC/IPC / Feuillet blanc CH COI / Άσπρη κάρτα/κάρτα έγκρισης Εταιρείας ADF
Pink card WADA / Feuillet rose AMA / I/OX, αντίγραφο Πρωτοκόπου Οργανισμού Αντιδότη
Green card IADOC / Doping Control Service / Feuillet vert / Service de contrôle du dopage ATHOC / Έγκριση αντίγραφο Έπισημο Δίπλωμα Ηθικής Αθλητικής
Yellow card Athlete / Feuillet jaune Sportif / Κίτρινο αντίγραφο Αθλητή
Blue card Laboratory / Feuillet bleu / Laboratoire / Μπλε αντίγραφο Εργαστήριο

STATEMENT OF CONSENT
I agree with my sample to be used anonymously for antidoping research purposes by any WADA accredited lab when all analysis have been completed and my sample would otherwise will be discarded.
Refusal of consent will bear no consequences for the athlete.
The Helsinki Accords and any applicable national standards as they relate to the involvement of human subjects in research will be followed.
 YES NO

DECLARATION DE CONSENTEMENT
J'accepte que mon échantillon soit utilisé pour des raisons de recherche antidopage par tous les laboratoires accrédités par l'AMA, une fois que toutes les analyses seront terminées et autrement mon échantillon serait jeté.
En cas de refus, cela n'entraîne aucune conséquence pour le sportif.
Les accords d'Helsinki et les normes nationales applicables en matière de recherche sur des sujets humains seront respectés.
 OUI NON

ΔΗΛΩΣΗ ΑΠΟΔΟΧΗΣ
Αποδέχομαι να χρησιμοποιηθεί το δείγμα μου για ερευνητικούς σκοπούς από οποιοδήποτε εργαστήριο πιστοποιημένο από τον WADA, όταν ολοκληρωθούν όλες οι αναλύσεις και διαφορετικά το δείγμα μου θα απορριφθεί.
Αρνηση αποδοχής δεν συνεπάγεται συνέπεια στον αθλητή.
Οι συμφωνίες του Ηελσίνκι και οι εθνικές κανονιστικές απαιτήσεις που αφορούν τη συμμετοχή ανθρώπων σε δοκιμές για ερευνητικούς σκοπούς.
 ΝΑΙ ΟΧΙ

1. Doping (DCOR)



PDF Complete

Your complimentary use period has ended.
Thank you for using PDF Complete.

[Click Here to upgrade to Unlimited Pages and Expanded Features](#)

TUE

doping.

(SG)

doping IST ("World Anti-Doping Agency. International Standard for Testing 3.0. Montreal: World Anti-Doping Agency; 2003"),

(SPSS v. 12.0; SPSS, Inc.,

Chicago, IL)

(product-moment)

Pearson


χ^2

t-test

(one-way ANOVA)

doping

(APG).



3.

APG, 64,2%

doping

3

80%

4

(4).

2,0±2,3


(: 2

= 11

, 147

= 1

).



4:

APG

(5),


166 doping (OOC)

, 24,4%

, 304 (21,7%))

32,0%

(IC),



5: /

APG

: AR: , AT: , BO: boccia, CR, CT, CY: , EQ: , FB: , GB: goalball, JU: , PO: , SA: , SH: , SW: , TT: , VS: , WB: , WF: , WR: rugby , WT: tennis

IC OOC ($\chi^2=14.0$, $df=1$, $p<0.001$).

IC OOC,

70%

OOC,



PDF Complete
 Your complimentary use period has ended.
 Thank you for using PDF Complete.
[Click Here to upgrade to Unlimited Pages and Expanded Features](#)

($\chi^2=83,7$, $df=17$, $p<0.001$). NSAIDs

IC (85,4% 80,0%,),

DCORs

(88,7%), (1,9%)

(1,7%). 6,7%

: (n=34), NSAIDs (n=17)

(n=13).

45% 29%, B,

(ATP, 25%).

($\chi^2=2385$, $df=102$, $p<0.001$).

, 4,8%

NSAIDs,

11,6% NSAIDs

($\chi^2=65.2$, $df=6$, $p<0.001$).

95,6% 87,6%

APG 3

NSAIDs 1,3 1,1

4

6

10

($\chi^2=1834$, $df=132$,

$p<0.001$), 86%

/ (SG).

2,2% SG

($r = 0,15$; $p<0.001$).


($t_{(711)}=2,399$; $p<0,05$),

SG

80%

>135

ml SG<1,015.



6:

DCORs

6.



PDF Complete
 Your complimentary use period has ended.
 Thank you for using PDF Complete.
[Click Here to upgrade to Unlimited Pages and Expanded Features](#)

(2,9%),

(1,4%).

: (n=11), (n=3),

(n=2), (n=1), -

(n=3), , 17

,

mildronate, . mildronate, ,

,

(Dambrova, Liepinsh, &

Kalvinsh, 2002; Sjakste, Gutcaits, & Kalvinsh, 2005).

, 20%

, 19% 19%

.

/

($x^2=96.7$, $df=51$, $p<0.001$),


($x^2=650.9$, $df=357$, $p<0.001$).

30-40 ,

NSAIDs , ,

.

Click Here to upgrade to Unlimited Pages and Expanded Features



7:

42,1%, (43,5%), /

(16,1%) / (10,5%)

(7).

, / 7 22

, 62,3%

1% doping APG

(9,1% 1,3%,).

NSAIDs APG (9,8%

5,6%,). 40% 6

NSAIDs DCORs (59%, Goalball 50%,

45,8%, 43%, 40%

44,4%). APG, 5,1%

NSAID ,

. NSAID acetaminophen

, oxycodone,


Click Here to upgrade to Unlimited Pages and Expanded Features

006.

NSAIDs

4,5%

NSAIDs.



8:

NSAIDs

NSAIDs

diclofenac (31,7%)

ibuprofen (15,2%),

22

NSAIDs

15 NSAIDs

COX-2 (COXIB)

4,9%

APG.

492 UEs

UEC

IPC.

184

-2-

, 279 GCSs, 11

, 11

8

UEs

6

-

GCS.

1. UE ("World

Observers Report, Paralympic Summer Games 2004").

O ,

IPC

/

-2 . , 184 (4,8%) 15

UEs 2- , salbutamol terbutaline

() formoterol salmeterol (

). salbutamol (78,9% UEs)

DCORs (54,2%). (12,2%), (11,6%) (9,8%)

2- (6).

DCORs 18 doping

2- UEs 2-

Doping,

2- 2- DCORs,

GCSs.

6. TUEs -2- APG

	TUE	-2-	%
AR	96	6	6,3
AT	1070	41	3,8
BO	86	6	7,0
CY	148	18	12,2
EQ	69	8	11,6
FB	153	4	2,6
GB	160	4	2,5
JU	118	6	5,1
PO	230	3	1,3
SA	72	-	0,0
SH	139	2	1,4
VS	157	6	3,8

Click Here to upgrade to Unlimited Pages and Expanded Features

	55	9,8
	4	1,7
	16	6,7
WF	-	0,0
WR	5	5,7
WT	-	0,0
	3827	184
		4,8

: AR: , AT: , BO: boccia, CR, CT, CY: , EQ: , FB: , GB: goalball, JU: , PO: , SA: , SH: , SW: , TT: , VS: , WB: , WF: , WR: rugby , WT: tennis

Doping, 1,6%

GCSs.

280

GCSs

UEs

155

(55,6%), 93

(33,0%), 15

(5,4%)

17

(6,1%)

GCS

prednisolone,

UEs

budesonide

betamethasone

Adverse Analytical

Findings (AAF)

(2 prednisolone, 1 budesonide)

UE.

6

gabapentin,

(diazepam, alprazolam, lorazepam), zopiclone

zolpidem

APG



PDF Complete
 Your complimentary use period has ended.
 Thank you for using PDF Complete.
[Click Here to upgrade to Unlimited Pages and Expanded Features](#)

(3459/06).

11 (68,8%) actovegin. , 44%

(Tsitsimpikou et al., 2009). H actovegin

2000,

US Postal Service

APG, ø

actovegin

doping

2000

doping

-Doping (ASADA)

APG 11



PDF Complete
 Your complimentary use period has ended.
 Thank you for using PDF Complete.
[Click Here to upgrade to Unlimited Pages and Expanded Features](#)

680

10 (2 8),

("2004 Post Games Report").

, 1155

893 (215 678) menu

. 3 -

doping,

81% APG

/ ,

63% ($x^2=41.7$, $df=1$, $p<0.001$). ,

doping , .

,

2004

($x^2=18.5$, $df=1$, $p<0.001$) ,

($x^2=14.0$, $df=1$, $p<0.001$).

2004,

APG (9,1%) 5,1% (Tsitsimpikou

et al., 2009).

,

(Ferrara & Davis, 1990;

Nilsen, Nygaard, & Bjirholt, 1985),



Your complimentary use period has ended.
Thank you for using PDF Complete.

[Click Here to upgrade to Unlimited Pages and Expanded Features](#)

NSAIDs

(11,1%),

(5.6%)

(3,7%) (Tsitsimpikou et al.,

2009).

COXIB

(Iezzi, Ferri, Mezzetti, &

Cipollone, 2007),

(Mukherjee, Nissen, & Topol, 2001).

4,9%

COXIB

16,5%

AOG.

,

,

NSAIDs (Ferrara et al.,

1992; Webborn, Willick, & Reeser, 2006).

,

AOG

NSAIDs

:

,

,

,

(Tsitsimpikou et al., 2009).

(Ferrara & Davis, 1990; Meyers, Brown, & Bloom, 2001b; Thuyne

& Delbeke, 2008b)

C6



PDF Complete
 Your complimentary use period has ended.
 Thank you for using PDF Complete.
 Click Here to upgrade to Unlimited Pages and Expanded Features

(- SCI)

(Klenck & Gebke, 2007).

(1.6%)

APG

(6/3806) 1/634

G

1/1173

2006 (1/1256)

2008 (1/1081).

DCORs.

(Bauman et al., 1992), \emptyset

(Dearwater et al., 1986; Filho, Salvetti, de Mello, da Silva, & Filho, 2006;

Mojtahedi, Valentine, Arngrimsson, Wilund, & Evans, 2008; Wilt et al., 2008).

-2-

PG (4.8%)

G, 4,6%

UES 4,2%

G

(Anderson et al., 2006).

-2-

(Fitch et al., 2008).

(Fitch et al.,

2008).

	7	TUEs	G	G.	TUEs
G	G.				
	7.	TUEs	G	G.	
APG					
			AAFs		AAFs
-2-	490 (4.6%)		29	180 (4.8%)	0
GCSs	1311		61	279	3
	0		0	11	0
	9 (1 insulin)		0	11 (6 insulin)	0
AAS	1		1	1	0
-	1		0	5	0
				13	
	7		0	(0
				oxycodone)	

(Bhambhani, 2002).



PDF Complete
Your complimentary use period has ended.
Thank you for using PDF Complete.
[Click Here to upgrade to Unlimited Pages and Expanded Features](#)

6).

(Rastmanesh, Taleban, Kimiagar,

Mehrabi, & Salehi, 2007).

APG,

(Tsitsimpikou et al., 2009).

placebo

(Perret, Mueller, & Knecht, 2006),

(9,1%)

(5,1%).

APG.

80%

Doping.

« » (õboostingõ).

(Schmid et al., 2001),

PG.



PDF Complete
Your complimentary use period has ended.
Thank you for using PDF Complete.
[Click Here to upgrade to Unlimited Pages and Expanded Features](#)

APG

G.

(Yekutiel, Brooks, Ohry,

Yarom, & Carel, 1989)

(Nelson et al., 1974; Pescatello et al., 2004).



PDF Complete
Your complimentary use period has ended.
Thank you for using PDF Complete.
[Click Here to upgrade to Unlimited Pages and Expanded Features](#)

PG

doping

OG.

« »

PG,

doping.

-2-

ø

ø



PDF
Complete

*Your complimentary
use period has ended.
Thank you for using
PDF Complete.*

[Click Here to upgrade to
Unlimited Pages and Expanded Features](#)

February, 2009, from www.

paralympic.org/release/Main_Sections_menu/IPC_Annual_Report

2004 Post Games Report. Retrieved February, 2009, from www.

paralympic.org/release/Main_Sections_menu

Alaranta, A., Alaranta, H., Heliövaara, M., Airaksinen, M., & Helenius, I. (2006). Ample use of physician-prescribed medications in Finnish elite athletes. *International journal of sports medicine*, 27(11), 919-925.

Almekinders, L. C. (1999). Anti-inflammatory treatment of muscular injuries in sport. An update of recent studies. *Sports medicine (Auckland, N.Z.)*, 28(6), 383-388.

Altman, A. J., Albert, D. M., & Fournier, G. A. (1985). Cocaine's use in ophthalmology: our 100-year heritage. *Survey of ophthalmology*, 29(4), 300-306.

Anderson, S. D., Sue-Chu, M., Perry, C. P., Gratziou, C., Kippelen, P., McKenzie, D. C., et al. (2006). Bronchial challenges in athletes applying to inhale a beta2-agonist at the 2004 Summer Olympics. *The Journal of allergy and clinical immunology*, 117(4), 767-773.

Baldwin Lanier, A. (2003). Use of nonsteroidal anti-inflammatory drugs following exercise-induced muscle injury. *Sports medicine (Auckland, N.Z.)*, 33(3), 177-185.

Bauman, W. A., Spungen, A. M., Raza, M., Rothstein, J., Zhang, R. L., Zhong, Y. G., et al. (1992). Coronary artery disease: metabolic risk factors and latent disease in individuals with paraplegia. *Mt Sinai J Med*, 59(2), 163-168.

Bhambhani, Y. (2002). Physiology of wheelchair racing in athletes with spinal cord injury. *Sports Med*, 32(1), 23-51.

A. C., Leblanc, B., Williams, R., Clark, M., et al. (1995).

Isometric and isokinetic exercise on the quadriceps muscle group.

Medicine and science in sports and exercise, 27(11), 1471-1476.

Corrigan, B., & Kazlauskas, R. (2003a). Medication use in athletes selected for doping control at the Sydney Olympics (2000). *Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine*, 13(1), 33-40.

Corrigan, B., & Kazlauskas, R. (2003b). Medication use in athletes selected for doping control at the Sydney Olympics (2000). *Clin J Sport Med*, 13(1), 33-40.

Dambrova, M., Liepinsh, E., & Kalvinsh, I. (2002). Mildronate: cardioprotective action through carnitine-lowering effect. *Trends in cardiovascular medicine*, 12(6), 275-279.

De Meersman, R. (1988). The effects of acetylsalicylic acid upon carbohydrate metabolism during exercise. *International journal of clinical pharmacology, therapy, and toxicology*, 26(9), 461-464.

Dearwater, S. R., LaPorte, R. E., Robertson, R. J., Brenes, G., Adams, L. L., & Becker, D. (1986). Activity in the spinal cord-injured patient: an epidemiologic analysis of metabolic parameters. *Med Sci Sports Exerc*, 18(5), 541-544.

Dec, K. L., Sparrow, K. J., & McKeag, D. B. (2000). The physically-challenged athlete: medical issues and assessment. *Sports medicine (Auckland, N.Z.)*, 29(4), 245-258.

Estorch, M., Carrião, I., Mena, E., Flotats, A., Camacho, V., Fuertes, J., et al. (2004). Challenging the neuronal MIBG uptake by pharmacological intervention: effect of a single dose of oral amitriptyline on regional cardiac MIBG uptake. *European journal of nuclear medicine and molecular imaging*, 31(12), 1575-1580.

European Parliament-Directive 2000/13/EC of the European Parliament and Council of 20th March 2000 on the approximation of the laws of the Member States relating to the

ertising of foodstuffs. Retrieved February, 2009, from
oj/dat/2000/1_109/1_10920000506en00290042.pdf

European Parliament-Directive 2002/46/EC of the European Parliament and Council of 10th

June 2002 on the approximation of the laws of the Member States relating to food
supplements. Retrieved February, 2009, from

<http://europa.eu/scadplus/leg/en/lvb/121102.htm>

Ferrara, M. S., Buckley, W. E., McCann, B. C., Limbird, T. J., Powell, J. W., & Robl, R.

(1992). The injury experience of the competitive athlete with a disability: prevention
implications. *Med Sci Sports Exerc*, 24(2), 184-188.

Ferrara, M. S., & Davis, R. W. (1990). Injuries to elite wheelchair athletes. *Paraplegia*,
28(5), 335-341.

Ferrara, M. S., & Peterson, C. L. (2000). Injuries to athletes with disabilities: identifying
injury patterns. *Sports Med*, 30(2), 137-143.

Filho, J. A., Salvetti, X. M., de Mello, M. T., da Silva, A. C., & Filho, B. L. (2006). Coronary
risk in a cohort of Paralympic athletes. *Br J Sports Med*, 40(11), 918-922.

Fitch, K. D., Sue-Chu, M., Anderson, S. D., Boulet, L. P., Hancox, R. J., McKenzie, D. C., et
al. (2008). Asthma and the elite athlete: summary of the International Olympic
Committee's consensus conference, Lausanne, Switzerland, January 22-24, 2008. *The
Journal of allergy and clinical immunology*, 122(2), 254-260, 260.e251-257.

Forgac, M. (1980). Carbohydrates loading - a review. *Journal of Applied Physiology*, 48, 624-
629.

Geyer, H., Parr, M. K., Mareck, U., Reinhart, U., Schrader, Y., & Schanzer, W. (2004).

Analysis of non-hormonal nutritional supplements for anabolic-androgenic steroids -
results of an international study. *Int J Sports Med*, 25(2), 124-129.

- vic, B. (2001). Analysis of over-the-counter dietary supplements. *Journal of Strength and Conditioning Research*, 11(4), 254-259.
- Grunewald, K. K., & Bailey, R. S. (1993). Commercially marketed supplements for bodybuilding athletes. *Sports medicine (Auckland, N.Z.)*, 15(2), 90-103.
- Haff, G. G., Lehmkuhl, M. J., McCoy, L. B., & Stone, M. H. (2003). Carbohydrate supplementation and resistance training. *Journal of strength and conditioning research / National Strength & Conditioning Association*, 17(1), 187-196.
- Helbling, A., Jenoure, P., & Mèuller, U. (1990). Hèufigkeit von Heuschnupfen bei Schweizer Spitzensportlern. *Schweizerische medizinische Wochenschrift*, 120(7), 231-236.
- History of Sport for Persons with a Disability. Retrieved February, 2009, from www.paralympic.org/release/Main_Sections_menu/About_the_IPC
- Huang, S. H., Johnson, K., & Pipe, A. L. (2006a). The use of dietary supplements and medications by Canadian athletes at the Atlanta and Sydney Olympic Games. *Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine*, 16(1), 27-33.
- Huang, S. H., Johnson, K., & Pipe, A. L. (2006b). The use of dietary supplements and medications by Canadian athletes at the Atlanta and Sydney Olympic Games. *Clin J Sport Med*, 16(1), 27-33.
- Iezzi, A., Ferri, C., Mezzetti, A., & Cipollone, F. (2007). COX-2: friend or foe? *Curr Pharm Des*, 13(16), 1715-1721.
- IPC Anti-Doping Code. Retrieved February, 2009, from www.paralympic.org/release/Main_Sections_menu/Anti_Doping
- IPC Brochure
Retrieved February, 2009, from www.paralympic.org/release/Main_Sections_menu/

- Joint Position Statement: nutrition and athletic performance. American College of Sports Medicine, American Dietetic Association, and Dietitians of Canada. (2000). *Medicine and science in sports and exercise*, 32(12), 2130-2145.
- Katellaris, C. H., Carrozzi, F. M., Burke, T. V., & Byth, K. (2006). Patterns of allergic reactivity and disease in Olympic athletes. *Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine*, 16(5), 401-405.
- Ken Fitch, & Kinsella, S. (2004). *A report to the IOC Medical Commission (IOC-MC) on ATUEs (Abbreviated Therapeutic Use Exemptions) for Glucocorticosteroids (GCS) at the Athens 2004 Olympic Games* o. Document Number)
- Klenck, C., & Gebke, K. (2007). Practical management: common medical problems in disabled athletes. *Clin J Sport Med*, 17(1), 55-60.
- Komarow, H. D., & Postolache, T. T. (2005). Seasonal allergy and seasonal decrements in athletic performance. *Clinics in sports medicine*, 24(2), e35-50, xiii.
- Kreider, R. B. (1999). Dietary supplements and the promotion of muscle growth with resistance exercise. *Sports medicine (Auckland, N.Z.)*, 27(2), 97-110.
- Kreider, R. B. (2003). Effects of creatine supplementation on performance and training adaptations. *Molecular and cellular biochemistry*, 244(1-2), 89-94.
- Krommydas, G., Gourgoulisanis, K. I., Karamitsos, K., Krapis, K., Kotrotsiou, E., & Molyvdas, P. A. (2005). Therapeutic value of antidepressants in asthma. *Medical hypotheses*, 64(5), 938-940.
- Kujala, U. M., Sarna, S., & Kaprio, J. (2003). Use of medications and dietary supplements in later years among male former top-level athletes. *Archives of internal medicine*, 163(9), 1064-1068.

atory events in asthma: an expanding equation. *The
l immunology*, 105(6), S633-636.

Martindale: The Complete Drug Reference. (April 1999). (32nd ed.). Paris: Pharmaceutical Press.

Martineau, L., Horan, M. A., Rothwell, N. J., & Little, R. A. (1992). Salbutamol, a beta 2-adrenoceptor agonist, increases skeletal muscle strength in young men. *Clinical science (London, England : 1979)*, 83(5), 615-621.

Mesa, J. L., Ruiz, J. R., González-Gross, M. M., Gutiérrez Sâainz, A., & Castillo Garzâon, M. J. (2002). Oral creatine supplementation and skeletal muscle metabolism in physical exercise. *Sports medicine (Auckland, N.Z.)*, 32(14), 903-944.

Meyers, M. C., Brown, B. R., & Bloom, J. A. (2001a). Fast pitch softball injuries. *Sports medicine (Auckland, N.Z.)*, 31(1), 61-73.

Meyers, M. C., Brown, B. R., & Bloom, J. A. (2001b). Fast pitch softball injuries. *Sports Med*, 31(1), 61-73.

Mojtahedi, M. C., Valentine, R. J., Arngrimsson, S. A., Wilund, K. R., & Evans, E. M. (2008). The association between regional body composition and metabolic outcomes in athletes with spinal cord injury. *Spinal Cord*, 46(3), 192-197.

Mukherjee, D., Nissen, S. E., & Topol, E. J. (2001). Risk of cardiovascular events associated with selective COX-2 inhibitors. *Jama*, 286(8), 954-959.

Nelson, R. R., Gobel, F. L., Jorgensen, C. R., Wang, K., Wang, Y., & Taylor, H. L. (1974). Hemodynamic predictors of myocardial oxygen consumption during static and dynamic exercise. *Circulation*, 50(6), 1179-1189.

Nieman, D. C. (2000). Exercise immunology: future directions for research related to athletes, nutrition, and the elderly. *International journal of sports medicine*, 21, S61-68.

- ... G. (1985). Complications that may occur in those with
... participate in sport. *Paraplegia*, 23(3), 152-158.
- Nyland, J., Snouse, S. L., Anderson, M., Kelly, T., & Sterling, J. C. (2000). Soft tissue
injuries to USA paralympians at the 1996 summer games. *Archives of physical
medicine and rehabilitation*, 81(3), 368-373.
- Nystad, W. (2000). Asthma. *International journal of sports medicine*, 21, S98-102.
- Paralympic Games. Retrieved February, 2009, from [www.
paralympic.org/release/Main_Sections_menu/Paralympic_Games](http://www.paralympic.org/release/Main_Sections_menu/Paralympic_Games)
- Perret, C., Mueller, G., & Knecht, H. (2006). Influence of creatine supplementation on 800 m
wheelchair performance: a pilot study. *Spinal Cord*, 44(5), 275-279.
- Pescatello, L. S., Franklin, B. A., Fagard, R., Farquhar, W. B., Kelley, G. A., & Ray, C. A.
(2004). American College of Sports Medicine position stand. Exercise and
hypertension. *Medicine and science in sports and exercise*, 36(3), 533-553.
- Phillips, S. M. (2004). Protein requirements and supplementation in strength sports. *Nutrition
(Burbank, Los Angeles County, Calif.)*, 20(7-8), 689-695.
- Price, M. J. (2006). Thermoregulation during exercise in individuals with spinal cord injuries.
Sports Med, 36(10), 863-879.
- Rahusen, F. T., Weinhold, P. S., & Almekinders, L. C. (2004). Nonsteroidal anti-
inflammatory drugs and acetaminophen in the treatment of an acute muscle injury.
The American journal of sports medicine, 32(8), 1856-1859.
- Rastmanesh, R., Taleban, F. A., Kimiagar, M., Mehrabi, Y., & Salehi, M. (2007). Nutritional
knowledge and attitudes in athletes with physical disabilities. *J Athl Train*, 42(1), 99-
105.
- Reynolds, J., Stirk, A., Thomas, A., & Geary, F. (1994). Paralympics--Barcelona 1992.
British journal of sports medicine, 28(1), 14-17.

- Spadari, G., Radice, D., Zecca, L., et al. (1994). Aspirin performance. *International journal of sports medicine*, 15(5), 224-227.
- Schmid, A., Schmidt-Trucksass, A., Huonker, M., Konig, D., Eisenbarth, I., Sauerwein, H., et al. (2001). Catecholamines response of high performance wheelchair athletes at rest and during exercise with autonomic dysreflexia. *Int J Sports Med*, 22(1), 2-7.
- Schwenk, T. L., & Costley, C. D. (2002). When food becomes a drug: nonanabolic nutritional supplement use in athletes. *The American journal of sports medicine*, 30(6), 907-916.
- Sjakste, N., Gutcaits, A., & Kalvinsh, I. (2005). Mildronate: an antiischemic drug for neurological indications. *CNS drug reviews*, 11(2), 151-168.
- Skouroliakou, M., Kani, C., Kompogiorgas, S., & Kontozamanis, V. (2005). Drug consumption during the 2004 Olympics: the special Olympic Pharmacy. *Pharmacy world & science : PWS*, 27(6), 478-479.
- Sobal, J., & Marquart, L. F. (1994a). Vitamin/mineral supplement use among athletes: a review of the literature. *International journal of sport nutrition*, 4(4), 320-334.
- Sobal, J., & Marquart, L. F. (1994b). Vitamin/mineral supplement use among high school athletes. *Adolescence*, 29(116), 835-843.
- Sports. Retrieved February, 2009, from [www. paralympic.org/release/Main_Sections_menu](http://www.paralympic.org/release/Main_Sections_menu)
- Stahl, S. M., & Grady, M. M. (2003). Differences in mechanism of action between current and future antidepressants. *The Journal of clinical psychiatry*, 64, 13-17.
- Storms, W. W. (1999). Exercise-induced asthma: diagnosis and treatment for the recreational or elite athlete. *Medicine and science in sports and exercise*, 31(1), S33-38.
- Szczeklik, A. (1987). Adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs. *Annals of allergy*, 59(5), 113-118.

A. S., Atkinson, M. H., Maksymowych, W., Huang, S.

-based approach to prescribing NSAIDs in

musculoskeletal disease: a Canadian consensus. *Canadian NSAID Consensus*

Participants. *CMAJ : Canadian Medical Association journal = journal de*

l'Association medicale canadienne, 155(1), 77-88.

Terjung, R. L., Clarkson, P., Eichner, E. R., Greenhaff, P. L., Hespel, P. J., Israel, R. G., et al.

(2000). American College of Sports Medicine roundtable. The physiological and health effects of oral creatine supplementation. *Medicine and science in sports and exercise*, 32(3), 706-717.

Thuyne, W. V., & Delbeke, F. T. (2008a). Declared use of medication in sports. *Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine*, 18(2), 143-147.

Thuyne, W. V., & Delbeke, F. T. (2008b). Declared use of medication in sports. *Clin J Sport Med*, 18(2), 143-147.

Tsitsimpikou, C., Tsiokanos, A., Tsarouhas, K., Schamasch, P., Fitch, K. D., Valasiadis, D., et al. (2009). Medication use by athletes at the Athens 2004 Summer Olympic Games. *Clin J Sport Med*, 19(1), 33-38.

Vacek, L. (1999). Is the level of pollutants a risk factor for exercise-induced asthma prevalence? *Allergy and asthma proceedings : the official journal of regional and state allergy societies*, 20(2), 87-93.

Volek, J. S., & Rawson, E. S. (2004). Scientific basis and practical aspects of creatine supplementation for athletes. *Nutrition (Burbank, Los Angeles County, Calif.)*, 20(7-8), 609-614.

). Morphine and other painkillers in relation to doping.

and Doping Risks of Nutritional Supplements and

Social Drugs, Cologne, Germany.

Webborn, N., Willick, S., & Reeser, J. C. (2006). Injuries among disabled athletes during the 2002 Winter Paralympic Games. *Med Sci Sports Exerc*, 38(5), 811-815.

Wilt, T. J., Carlson, K. F., Goldish, G. D., MacDonald, R., Niewoehner, C., Rutks, I., et al. (2008). Carbohydrate and lipid disorders and relevant considerations in persons with spinal cord injury. *Evid Rep Technol Assess (Full Rep)*(163), 1-95.

Woodhouse, J. M., Adler, P., & Duignan, A. (2004). Vision in athletes with intellectual disabilities: the need for improved eyecare. *Journal of intellectual disability research : JIDR*, 48(Pt), 736-745.

World Anti-Doping Agency, Independent Observers Report, Paralympic Summer Games 2004. Retrieved February, 2009, from www.wada-ama.org

World Anti-Doping Agency, International Standard for Laboratories, 2004. Retrieved February, 2009, from www.wada-ama.org

World Anti-Doping Agency, International Standard for Therapeutic Use Exemptions 3.0, 2003. Retrieved February, 2009, from www.wada-ama.org

World Anti-Doping Agency, International Standard List of Prohibited Substances and Methods.

World Anti-Doping Agency. International Standard for Testing 3.0. Montreal: World Anti-Doping Agency; 2003. Retrieved February, 2009, from www.wada-ama.org

Yekutieli, M., Brooks, M. E., Ohry, A., Yarom, J., & Carel, R. (1989). The prevalence of hypertension, ischaemic heart disease and diabetes in traumatic spinal cord injured patients and amputees. *Paraplegia*, 27(1), 58-62.



*Your complimentary
use period has ended.
Thank you for using
PDF Complete.*

[Click Here to upgrade to
Unlimited Pages and Expanded Features](#)